Protara Therapeutics Inc. Common Stock (TARA)

About TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an invest…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

46

Website

protaratx.com/

Fundamentals

1-day range

$3.79$3.99

Market cap

$223.13M

P/E (trailing)

—

P/E (forward)

-2.26

EPS (trailing)

$-1.35

Dividend yield

—

Beta

1.46

Avg. volume

560.8K

Dividend pay date

January 10, 2020

Forecasts

7 analyst ratings

Protara Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• TARA

  Protara Therapeutics Inc. Common Stock

  $3.82

  ▼ 4.26%
  Market cap $223.13MP/E —
  $3.02$7.82
• SRZN

  Surrozen Inc. Common Stock

  $22.42

  ▼ 6.62%
  Market cap $252.87MP/E —
  $10.73$35
• EDIT

  Editas Medicine Inc. Common Stock

  $3.15

  ▼ 4.55%
  Market cap $259.45MP/E —
  $1.66$4.54
• ARMP

  Armata Pharmaceuticals Inc. Common Stock

  $5.24

  ▼ 3.50%
  Market cap $185.39MP/E —
  $2.4$16.34
• VYGR

  Voyager Therapeutics Inc. Common Stock

  $3.54

  ▲ 2.17%
  Market cap $181.26MP/E —
  $2.94$5.55
• AVXL

  Anavex Life Sciences Corp. Common Stock

  $2.98

  ▼ 4.79%
  Market cap $273.38MP/E —
  $2.26$10.4
• LCTX

  Lineage Cell Therapeutics Inc. Common Stock

  $1.11

  ▼ 4.31%
  Market cap $276.72MP/E —
  $1$2.09

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Protara Therapeutics Q2 EPS $(0.36) Misses $(0.33) Estimate
  benzinga · 8/11/2026
• Protara Therapeutics Q2 EPS $(0.36) Misses $(0.33) Estimate
  Benzinga · 8/11/2026
• Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline
  SeekingAlpha · 8/11/2026

• Jesse Shefferman · June 30, 2026 · Gift

  5.0K
• Jesse Shefferman · June 30, 2026 · Gift

  4.0K
• Jesse Shefferman · June 30, 2026 · Gift

  7.0K
• Jesse Shefferman · June 30, 2026 · Gift

  14.0K
• Jesse Shefferman · June 29, 2026 · Option Exercise

  215.7K @ $1.91
• Jesse Shefferman · June 29, 2026 · Sale

  215.7K @ $4.09
• Richard S. Levy · June 15, 2026 · Grant

  31.0K
• Solomon Michael Edward · June 15, 2026 · Grant

  31.0K
• Smith Cynthia · June 15, 2026 · Grant

  31.0K
• Jane Huang · June 15, 2026 · Grant

  31.0K
• GARCEAU ROGER · June 15, 2026 · Grant

  31.0K
• Flannelly Barry P · June 15, 2026 · Grant

  31.0K
• SARGEN GREGORY · June 15, 2026 · Grant

  31.0K
• BESHAR LUKE M · June 15, 2026 · Grant

  31.0K
• William Conkling · June 2, 2026 · Tax Withholding

  6.0K @ $4.34

Institutional Ownership

March 31, 2026

Total shares held

44.87M

Total value held

$233.54M

Institutional holders

109